Аннотация:
Introduction: The objective of this study was to assess the impact of a single-pill combination (SPC) of perindopril/indapamide (PER/IND) at full doses (10/2.5 mg) on endothelial and cognitive function as a clinical intermediate marker of vascular improvement. Methods: This open-label, uncontrolled, observational study enrolled 30 patients (20 females and 10 males) with grade II–III uncontrolled arterial hypertension (SBP/DBP ≥ 160/100 mmHg) and no evidence of cerebrovascular disease. All patients underwent assessment of macro- and microvascular endothelial function parameters at baseline and after 12 months of treatment with SPC PER/IND using photoplethysmography and video capillaroscopy. Cognitive function was assessed using the Montreal Cognitive Assessment scale (MoCA). Results: All patients (mean age 60.06 ± 10.19 years) were at high risk for cardiovascular events: mean body mass index (BMI) 31.2 ± 3.9 kg/m2, 33[%] diagnosed with coronary artery disease angina class I, 30[%] with impa
Ключевые слова:
Antihypertensive therapy; Cardiology; Hypertension; Indapamide; Perindopril
acetylsalicylic acid; angiotensin receptor antagonist; beta adrenergic receptor blocking agent; dipeptidyl carboxypeptidase inhibitor; glucose; hydroxymethylglutaryl coenzyme A reductase inhibitor; indapamide plus perindopril; low density lipoprotein cholesterol; perindopril; antihypertensive agent; indapamide; indapamide, perindopril drug combination; perindopril; adult; aged; angina pectoris; antihypertensive therapy; Article; blood vessel wall; body mass; capillaroscopy; capillary network density; cardiovascular parameters; cardiovascular risk; cholesterol blood level; clinical article; clinical trial; cognition; cognitive defect; combination drug therapy; coronary artery disease; coughing; diastolic blood pressure; drug safety; drug tolerability; drug withdrawal; endothelial dysfunction; essential hypertension; family history; female; glucose blood level; health care; heart ventricle remodeling; high risk patient; human; hyperemia; impaired glucose tolerance; low density lipoprotei
Zhelezny'kh E. A. Elena Anatolyevna 1965-
Danilogorskaya Yu. A. Yuliya Aleksandrovna 1972-
Privalova E. V. Elena Vitalyevna 1958-
Belenkov Yu. N. Yurij Nikitich 1948-
Schendrygina A. A.
Il`gisonis I. S. Irina Sergeevna 1983-
Pavlov N. A.
Tishman M. I.
Железных Е. А. Елена Анатольевна 1965-
Данилогорская Ю. А. Юлия Александровна 1972-
Привалова Е. В. Елена Витальевна 1958-
Беленков Ю. Н. Юрий Никитич 1948-
Счендрyгина А. А.
Ильгисонис И. С. Ирина Сергеевна 1983-
Павлов Н. А.
Тишман М. И.
Combination Antihypertensive Therapy with Perindopril and Indapamide in Patients with Essential Hypertension: Effect on Endothelial and Cognitive Markers of Vascular Improvement
Combination Antihypertensive Therapy with Perindopril and Indapamide in Patients with Essential Hypertension: Effect on Endothelial and Cognitive...
Текст визуальный непосредственный
Advances in Therapy
Health Communications, Inc.
Vol.35, Issue10 P. 1698-1712
2018
Статья
Antihypertensive therapy Cardiology Hypertension Indapamide Perindopril
acetylsalicylic acid angiotensin receptor antagonist beta adrenergic receptor blocking agent dipeptidyl carboxypeptidase inhibitor glucose hydroxymethylglutaryl coenzyme A reductase inhibitor indapamide plus perindopril low density lipoprotein cholesterol perindopril antihypertensive agent indapamide indapamide, perindopril drug combination perindopril adult aged angina pectoris antihypertensive therapy Article blood vessel wall body mass capillaroscopy capillary network density cardiovascular parameters cardiovascular risk cholesterol blood level clinical article clinical trial cognition cognitive defect combination drug therapy coronary artery disease coughing diastolic blood pressure drug safety drug tolerability drug withdrawal endothelial dysfunction essential hypertension family history female glucose blood level health care heart ventricle remodeling high risk patient human hyperemia impaired glucose tolerance low density lipoprotei
Introduction: The objective of this study was to assess the impact of a single-pill combination (SPC) of perindopril/indapamide (PER/IND) at full doses (10/2.5 mg) on endothelial and cognitive function as a clinical intermediate marker of vascular improvement. Methods: This open-label, uncontrolled, observational study enrolled 30 patients (20 females and 10 males) with grade II–III uncontrolled arterial hypertension (SBP/DBP ≥ 160/100 mmHg) and no evidence of cerebrovascular disease. All patients underwent assessment of macro- and microvascular endothelial function parameters at baseline and after 12 months of treatment with SPC PER/IND using photoplethysmography and video capillaroscopy. Cognitive function was assessed using the Montreal Cognitive Assessment scale (MoCA). Results: All patients (mean age 60.06 ± 10.19 years) were at high risk for cardiovascular events: mean body mass index (BMI) 31.2 ± 3.9 kg/m2, 33[%] diagnosed with coronary artery disease angina class I, 30[%] with impa